EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis

Vicente Morales Ribeiro iD, Douglas Nunes Cavalcante iD, Hermes Estevam Torega Celkevicius iD, Giovanna Cristina Gonçalves Camacho iD, Henrique Alexsander Ferreira Neves iD, Kevlin de Souza iD, Rafael Henkes Machado iD, Lucca Moreira Lopes iD, Webster Donaldy iD, Luiz Aparecido Bortolotto iD, Jamil Cherem Schneider

American Journal of Hypertension · 01.07.2026 · 39 (7) · 911-920

DOI: 10.1093/ajh/hpaf246 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Hypertension, online erschienen am 22.12.2025. Verfasst von Vicente Morales Ribeiro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Southern Santa Catarina, Palhoça, Brazil. Hauptthemen laut MEDLINE: Hypertension, Blood Pressure, Antihypertensive Agents, Benzazepines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy and safety of lorundrostat, a selective aldosterone synthase inhibitor, in patients with uncontrolled hypertension remain unclear. This meta-analysis aimed to evaluate its effects on blood pressure and risk of hyperkalemia.

Methods

PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were systematically searched through July 2025 for randomized controlled trials comparing lorundrostat with placebo. Pooled mean differences (MD) and risk ratios (RR) with 95% CIs were estimated using a random-effects model with the Restricted Maximum Likelihood estimator. Trial sequential analysis (TSA) was conducted to assess the conclusiveness of safety evidence.

Results

Three RCTs including 1060 patients were identified. Lorundrostat significantly reduced systolic blood pressure at 50 mg (MD, −9.08 mmHg; 95% CI, −13.14 to −5.03) and 100 mg (MD, −11.41 mmHg; 95% CI, −15.97 to −6.85), and diastolic blood pressure at 50 mg (MD, −3.48 mmHg; 95% CI, −5.98 to −0.98). However, lorundrostat increased the risk of hyperkalemia at 50 mg (RR, 6.56; 95% CI, 1.53-28.12; NNH = 71) and 100 mg (RR, 10.37; 95% CI, 2.44-44.03; NNH = 42). TSA confirmed hyperkalemia at 100 mg as the only conclusive harm signal, while other safety outcomes remained inconclusive.

Conclusions

Lorundrostat effectively lowered blood pressure but increased dose-dependent risk of hyperkalemia. These findings support its potential as a novel therapy for uncontrolled hypertension, while emphasizing the need for longer-term cardiovascular outcome trials and direct comparisons with mineralocorticoid receptor antagonists concerning efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionBlood PressureAntihypertensive AgentsBenzazepinesCytochrome P-450 CYP11B2HumansTreatment OutcomeRandomized Controlled Trials as TopicHyperkalemia

Stichwörter der Autor:innen

aldosterone synthase inhibitorsdrug therapyhypertensionmeta-analysisrandomized controlled trialstreatment outcome

Substanzen

Antihypertensive AgentsBenzazepinesCytochrome P-450 CYP11B2

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Southern Santa Catarina, Palhoça, Brazil.
  • Albert Einstein Israeli Institute of Education and Research (IIEP), Hospital Israelita Albert Einstein, Goiânia, Brazil.
  • Department of Internal Medicine, Serra Gaúcha University Center, Caxias do Sul, Brazil.
  • Department of Internal Medicine, Federal University of Paraná, Curitiba, Brazil.
  • Department of Internal Medicine, Redentor University Center, Itaperuna, Brazil.
  • Department of Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

ORCID-Profile: Vicente Morales Ribeiro, Douglas Nunes Cavalcante, Hermes Estevam Torega Celkevicius, Giovanna Cristina Gonçalves Camacho, Henrique Alexsander Ferreira Neves, Kevlin de Souza, Rafael Henkes Machado, Lucca Moreira Lopes, Webster Donaldy, Luiz Aparecido Bortolotto

Zitieren

APA

Ribeiro, V. M., Cavalcante, D. N., Celkevicius, H. E. T., Camacho, G. C. G., Neves, H. A. F., de Souza, K., Machado, R. H., Lopes, L. M., Donaldy, W., Bortolotto, L. A., & Schneider, J. C. (2026). Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. American Journal of Hypertension, 39(7), 911-920. https://doi.org/10.1093/ajh/hpaf246

Vancouver

Ribeiro VM, Cavalcante DN, Celkevicius HET, Camacho GCG, Neves HAF, de Souza K, et al. Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. American Journal of Hypertension. 2026;39(7):911-920. doi:10.1093/ajh/hpaf246

BibTeX
@article{Ribeiro2026,
  author = {Ribeiro, Vicente Morales and Cavalcante, Douglas Nunes and Celkevicius, Hermes Estevam Torega and Camacho, Giovanna Cristina Gonçalves and Neves, Henrique Alexsander Ferreira and de Souza, Kevlin and Machado, Rafael Henkes and Lopes, Lucca Moreira and Donaldy, Webster and Bortolotto, Luiz Aparecido and Schneider, Jamil Cherem},
  title = {Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis},
  journal = {American Journal of Hypertension},
  year = {2026},
  volume = {39},
  number = {7},
  pages = {911--920},
  doi = {10.1093/ajh/hpaf246}
}
Kostenlos starten →